An actively recruiting phase 1/2 trial assessing HPN328, a trispecific T-cell engager targeting DLL3 for patients with DLL3-SCLC has shown promising interim results (NCT04471727) with tumor shrinkage and one confirmed partial response. Here, DLL3 is linked to small cell lung carcinoma.